• Tieyuan Zhang, Jinjuan Zhao, Yanjun Guan, Xiangling Li, Jun Bai, Xiangyu Song, Zhibo Jia, Shengfeng Chen, Chaochao Li, Yifan Xu, Jiang Peng, and Yu Wang.
• Beijing Key Lab of Regenerative Medicine in Orthopedics, Key Laboratory of Musculoskeletal Trauma and War Injuries PLA, Department of Orthopedics, the Fourth Medical Center, Chinese PLA General Hospital, Beijing 100048, China; Medical School of Chinese PLA, Beijing 100853, China.
• Neuroscience. 2023 Aug 1; 524: 149157149-157.

AbstractDeferoxamine (DFO) is a potent iron chelator for clinical treatment of various diseases. Recent studies have also shown its potential to promote vascular regeneration during peripheral nerve regeneration. However, the effect of DFO on the Schwann cell function and axon regeneration remains unclear. In this study, we investigated the effects of different concentrations of DFO on Schwann cell viability, proliferation, migration, expression of key functional genes, and axon regeneration of dorsal root ganglia (DRG) through a series of in vitro experiments. We found that DFO improves Schwann cell viability, proliferation, and migration in the early stages, with an optimal concentration of 25 μM. DFO also upregulates the expression of myelin-related genes and nerve growth-promoting factors in Schwann cells, while inhibiting the expression of Schwann cell dedifferentiation genes. Moreover, the appropriate concentration of DFO promotes axon regeneration in DRG. Our findings demonstrate that DFO, with suitable concentration and duration of action, can positively affect multiple stages of peripheral nerve regeneration, thereby improving the effectiveness of nerve injury repair. This study also enriches the theory of DFO promoting peripheral nerve regeneration and provides a basis for the design of sustained-release DFO nerve grafts.Copyright © 2023 IBRO. Published by Elsevier Ltd. All rights reserved.

23 keywords...

hide…